I agree, I dislike Reverse Splits, very seldom does it work out. And if the data isn't good we go to zero pretty fast.
If the data is so so, who knows. If we see the FDA delaying wanted more information even with TLD we still may tank. If we were a large pharma it would be a simpler path with the FDA, in my opinion.
I am sure you are diversified in case we do tank, I am but this would still sting for sure. But some have it all in NWBO. That really surprises me as this is not a slam dunk.
Have a Healthy and Prosperous New Year!
Market Data 
Markets 
AI
